Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Patient reported outcomes: looking beyond the label claim

16 references·6 citing·36 second hop

FromToDepth

this work references cited by second hop

References

1992The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.33,714 cited
1990EuroQol - a new facility for the measurement of health-related quality of life15,736 cited
1993What is coefficient alpha? An examination of theory and applications.8,803 cited
1961Probabilistic Models for Some Intelligence and Attainment Tests6,956 cited
1993The MOS 36-Item Short-Form Health Survey (SF-36)6,667 cited
1993Measuring Health-Related Quality of Life3,970 cited
2008Health Measurement Scales2,628 cited
1994A Critical Appraisal of the Quality of Quality-of-Life Measurements2,209 cited
1982Probabilistic Models for some Intelligence and Attainment Tests.1,979 cited
2004Citizen Participation in Decision Making: Is It Worth the Effort?1,937 cited
2003Health Measurement Scales1,459 cited
2007Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective726 cited
2003Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001515 cited
2004Application of Rasch Analysis in the Development and Application of Quality of Life Instruments449 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

1989Measuring quality of life in clinical trials: a taxonomy and review.410 cited

2003The development of health technology assessment334 cited

Cited by

2015Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review141 cited
2016Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries82 cited
2013Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006–2010)79 cited
2020Mind the methods of determining minimal important differences: three critical issues to consider73 cited
2017Development of a new Rasch-based scoring algorithm for the National Eye Institute Visual Functioning Questionnaire to improve its interpretability40 cited
2018Evaluating methodological quality of Prognostic models Including Patient-reported HeAlth outcomes iN oncologY (EPIPHANY): a systematic review protocol12 cited